Compare SGHT & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGHT | SPXX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.0M | 331.3M |
| IPO Year | 2021 | 2005 |
| Metric | SGHT | SPXX |
|---|---|---|
| Price | $5.20 | $18.07 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.08 | N/A |
| AVG Volume (30 Days) | 129.1K | ★ 243.9K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,363,000.00 | N/A |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $10.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.11 | $15.78 |
| 52 Week High | $9.24 | $18.53 |
| Indicator | SGHT | SPXX |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 53.02 |
| Support Level | $4.76 | $17.63 |
| Resistance Level | $5.66 | $18.14 |
| Average True Range (ATR) | 0.30 | 0.24 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 95.52 | 45.52 |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35% to 75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.